Content Type: Article

  • Irreparable harm? Don’t bury your trade secret

    Irreparable harm? Don’t bury your trade secret

    ARTICLE

    Irreparable harm? Don’t bury your trade secret

    Aug 6, 2026

    Read time: 3 min

    Key takeaways
    Overview

    The US Court of Appeals for the Eighth Circuit affirmed the denial of a preliminary injunction, finding that the district court did not abuse its discretion in concluding that the plaintiff’s asserted harms, including lost profits and injury from the alleged trade secret injury, could be adequately remedied through monetary damages. Revenue Management Solutions, LLC v. Commerce Bank, Case No. 25-3159 (8th Cir. July 23, 2026) (Gruender, Benton, Erickson, JJ.)

    Revenue Management Solutions (RMS) licensed to Commerce Bank software that processes and organizes records and payment information. Commerce marketed the software under the name RemitConnect. Under the parties’ license agreement, Commerce received access to RMS’s confidential software and source code but was prohibited from copying or disclosing the software or source code, reverse engineering the software, or creating derivative works based on RMS’s proprietary technology.

    In 2018, Commerce began developing its own software, RemitConnect 2.0. By 2025, RMS observed a decline in Commerce’s use of the licensed version of its software. Suspecting that Commerce had reverse engineered and copied its software, RMS moved for a preliminary injunction to prohibit Commerce from using RemitConnect 2.0. The district court denied the motion, concluding that RMS failed to present sufficient evidence of irreparable harm. RMS appealed.

    RMS argued that the district court failed to recognize the irreparable harm resulting from Commerce’s misappropriation of its trade secrets. RMS asserted claims under the Defend Trade Secrets Act and the Missouri Uniform Trade Secrets Act, identifying two categories of trade secrets: sets of input-output data and segregation logic. According to RMS, Commerce misappropriated those trade secrets in developing RemitConnect 2.0.

    The Eighth Circuit noted that the district court did not expressly discuss RMS’s trade secrets in its irreparable-harm analysis. The Court explained that RMS itself framed its alleged harm primarily as lost profits, referring to the misuse and disclosure of its trade secrets only in passing through a few parenthetical references. By characterizing its injury in terms of lost profits, RMS permitted the district court to conclude that any potential harm could be adequately remedied by an award of damages. The Eight Circuit thus concluded that the district court did not clearly err in finding that RMS failed to demonstrate irreparable harm.

    Practice note: Although the loss, misuse, or disclosure of trade secrets may constitute irreparable harm, a plaintiff seeking injunctive relief should clearly articulate how the alleged misappropriation causes harm that cannot be adequately remedied by monetary damages. Framing the injury primarily as lost profits or another quantifiable economic loss may undermine the argument that preliminary injunctive relief is necessary.

    Authors

    Jodi Benassi

    Partner

    San Francisco

    More insights
    Endnotes

  • Latest tax updates: Charitable donation scrutiny, regulation invalidity, and codified economic substance guidance

    Latest tax updates: Charitable donation scrutiny, regulation invalidity, and codified economic substance guidance

    ARTICLE

    Latest tax updates: Charitable donation scrutiny, regulation invalidity, and codified economic substance guidance

    August 4, 2026

    Read time: 7 min

    Key takeaways
    Overview

    This edition of IRS Roundup covers recent administrative guidance, examination trends, and US Tax Court developments. The Internal Revenue Service (IRS) released updated pension-related interest rates and August applicable federal rates (AFRs) while practitioners reported increased examination activity involving noncash charitable contributions. The Tax Court also invalidated the US Department of the Treasury’s extraordinary disposition rules under § 245A, addressed the application of the codified economic substance doctrine in a captive-insurance dispute, and clarified the valuation of gifts arising from the termination of a qualified terminable interest property (QTIP) trust.

    In depth

    IRS guidance

    July 14, 2026: The IRS issued Notice 2026-44, providing the June 2026 corporate bond monthly yield curve and spot segment rates under § 417(e)(3), the 24-month average segment rates applicable for July 2026 under § 430, and the 30-year Treasury weighted average used for certain multiemployer plan calculations under § 431. The June 2026 spot segment rates are 4.49%, 5.43%, and 6.18%.

    For July 2026, the unadjusted 24-month average segment rates are 4.37%, 5.27%, and 5.93%. The adjusted rates applicable to plan years beginning in 2026 are 4.75%, 5.25%, and 5.93%. For plan years beginning in July 2026, the 30-year Treasury weighted average is 4.56%, with a permissible range of 4.10% to 4.78%.

    July 15, 2026: The IRS issued Revenue Ruling 2026-13, providing the AFRs for August 2026, including short-, mid-, and long-term AFRs under § 1274; adjusted AFRs under § 1288; and rates applicable under §§ 382, 42, and 7520. The ruling sets the § 7520 rate at 5.20% and the adjusted federal long-term rate under § 382 at 3.72%, with the long-term tax-exempt rate at 3.77%.

    The ruling also provides the low-income housing credit percentages for August 2026, including an 8.08% rate for the 70% present value credit and a 3.46% rate for the 30% present value credit, along with the monthly AFR tables used for federal tax valuation, financing, estate planning, and other tax calculations.

    Examination trends

    July 20, 2026: Tax controversy practitioners are reporting a renewed wave of IRS examinations targeting noncash charitable contributions, particularly donations involving hard-to-value assets such as art, intellectual property, privately held businesses, medical supplies, and other property susceptible to inflated valuations. The increased audit activity follows the IRS’s recent efforts to combat syndicated conservation easement transactions and suggests that agents with experience challenging valuation-based charitable deductions are now expanding their focus to other types of contribution arrangements. The renewed enforcement comes despite significant workforce reductions and leadership turnover at the agency.

    Practitioners report that many of these examinations focus less on disputing an asset’s fair market value and more on identifying technical defects that can invalidate a deduction, such as failures to obtain a qualified appraisal, satisfy substantiation requirements, or comply with filing deadlines. The development also aligns with the Trump administration’s stated enforcement priority of increasing scrutiny of tax-exempt organizations and charitable-contribution abuses. According to IRS data, taxpayers claimed deductions for more than $160 billion in noncash charitable contributions in 2023, with a substantial portion attributable to high-income taxpayers, making charitable valuation issues an increasingly significant area of IRS enforcement.

    Case developments

    July 15, 2026: In Siemens Medical Solutions USA, Inc. v. Commissioner, 167 T.C. No. 5, the Tax Court held that Siemens was entitled to a full dividends-received deduction under § 245A, concluding that Treasury’s extraordinary disposition rules in Temp. Treas. Reg. § 1.245A-5T are invalid because they conflict with the unambiguous text of the statute. The Court determined that extraordinary disposition rules amounted to an impermissible override of the statute’s effective dates.

    The dispute arose because Siemens’ foreign subsidiary realized significant gains from related-party asset sales in 2018, increasing its earnings and profits before distributing a foreign-source dividend to its US parent in 2019. Although the dividend satisfied every statutory requirement for the § 245A deduction, the IRS invoked the extraordinary disposition rules to disallow approximately $315 million of the deduction, asserting that the underlying earnings fell within a transition-period gap between the mandatory repatriation tax (§ 965) and the global intangible low-taxed income (GILTI) regime (§ 951A). Relying heavily on its earlier decision in Varian Medical Systems and the Supreme Court’s decision in Loper Bright, the Tax Court emphasized that courts – not agencies – must determine the best reading of a statute. Because Congress expressly made § 245A applicable to distributions made after December 31, 2017, the Court concluded that Treasury lacked authority to rewrite that rule through regulation, even if it believed Congress had inadvertently created a gap in the Tax Cuts and Jobs Act’s effective dates.

    July 20, 2026: In Beveled Edge Insurance Company, Inc. v. Commissioner, Docket No. 19821-16 et al. (T.C. Order July 20, 2026), the Tax Court denied the taxpayers’ motion for partial summary judgment in which it argued that the IRS could not simultaneously assert that a captive insurance arrangement lacked economic substance while also treating purported insurance premiums as taxable income and asserting economic substance penalties. The taxpayer had argued that the IRS’s position constituted an impermissible “whipsaw” because the transaction either had economic substance for all purposes or for none. The Court, however, decided that the economic substance doctrine does not necessarily disregard an entire transaction for all federal tax purposes. Instead, as codified in § 7701(o), the Court held that the doctrine operates to deny tax benefits associated with transactions lacking economic substance while allowing economically substantive aspects of the transaction to retain their normal tax consequences.

    The Court also held that, even if the IRS’s theories were viewed as inconsistent, the IRS commissioner is generally permitted to plead inconsistent positions. Finally, the Court declined to strike the § 6662 economic substance penalties, concluding that whether the taxpayers had a substantial non-tax business purpose under § 7701(o) presents a factual issue that must be resolved at trial rather than on summary judgment.

    July 20, 2026: In Lewis v. Commissioner, T.C. Memo. 2026-58, the Tax Court determined the value of taxable gifts made by two children who agreed to terminate a QTIP trust and allow their father to receive all of the trust assets. Building on a prior 2024 decision holding that the children had made taxable gifts, the Court held that the value of each gift was $35,141,321. In reaching that result, the Court rejected the IRS’s position that the § 7520 actuarial tables controlled the valuation and instead held that the beneficiaries’ rights under the trust were determined by state law, not by federal valuation tables. The Court also concluded that the value of the gifts should be reduced by the children’s avoided obligation under § 2207A to reimburse their father for gift tax that would have arisen had the trust terminated according to its terms.

    The Court also rejected the taxpayers’ arguments that the gifts had only nominal value because their father held a limited testamentary power of appointment and their valuation expert treated him as having a longer-than-average life expectancy due to his high income. The Court held that the father’s limited power of appointment did not diminish the children’s entitlement under the trust instrument when interpreted in accordance with the testator’s intent under Washington law. The Court also found that the expert lacked a sufficient factual basis to depart from standard actuarial life expectancy assumptions based solely on the father’s wealth and income. The decision provides important guidance on valuing transfers involving QTIP trusts, emphasizing that state law determines the underlying property rights while federal tax law governs the resulting gift-tax consequences.

    Authors

    Kai M. Fenty

    Associate

    Chicago

    Akiva B. Ungar

    Associate

    Chicago

    Edward L. Froelich

    Counsel

    Washington, DC

    More insights
    Endnotes

  • Utah’s targeted advertising tax heads to court

    Utah’s targeted advertising tax heads to court

    ARTICLE

    Utah’s targeted advertising tax heads to court

    Jul 30, 2026

    Read time: 4 min

    Key takeaways
    Overview

    On July 28, 2026, McDermott Will & Schulte, together with Holland & Hart, filed a verified complaint on behalf of the Utah Taxpayers Association challenging Utah’s new targeted advertising tax. The lawsuit asks the Third Judicial District Court in Salt Lake County to declare the tax unlawful and unconstitutional and permanently enjoin the Utah State Tax Commission from enforcing it. Because the action challenges the constitutionality of a Utah statute, state law requires the case to be heard by a three-judge district court panel.

    Enacted earlier this year as Senate Bill 287 and codified at Utah Code Ann. § 59-35-201, Utah’s tax borrows from Maryland’s digital advertising gross receipts tax but applies specifically to receipts from “targeted advertising.” The law imposes a 4.7% tax on Utah gross receipts from targeted advertising earned by an entity that derives at least:

    • $1 million in annual gross receipts from targeted advertising in Utah
    • $100 million in annual gross receipts from targeted advertising worldwide
    • 50% of its total worldwide gross receipts from targeted advertising.

    The tax applies to taxable periods beginning on or after January 1, 2027.

    Although the statute describes targeted advertising as the delivery of an advertisement “by any means,” the law’s cumulative definitions limit the tax to advertising delivered over the internet. Similar advertising delivered through newspapers, radio, television, billboards, and other non-internet channels is not subject to the tax.

    The complaint asserts four claims:

    • The tax is preempted by the federal Internet Tax Freedom Act (ITFA), which prohibits states from imposing discriminatory taxes on e-commerce. Utah’s tax violates ITFA because it applies to advertising delivered over the internet while leaving comparable advertising delivered through other channels untaxed.
    • The tax is independently barred by ITFA’s prohibition against taxes on “Internet access.” ITFA’s definition of internet access includes certain independently provided content, such as “video clips.” Because Utah’s definition of an advertisement reaches video advertisements delivered over the internet, the tax reaches receipts from internet access itself.
    • The tax discriminates against interstate commerce in violation of the Commerce Clause of the US Constitution. No Utah-domiciled business satisfies the law’s worldwide gross-receipts thresholds. Utah businesses earning targeted advertising receipts below those thresholds therefore remain untaxed while larger out-of-state businesses engaging in the same activity are subject to the tax.
    • The worldwide gross-receipts thresholds violate due process. Whether an entity owes the Utah tax may depend on receipts and business activities occurring entirely outside Utah, even when those activities have no connection to the state. Utah may not use those extraterritorial activities to determine whether an entity’s Utah receipts are taxable.

    Utah is part of a broader pattern. Maryland’s digital advertising gross receipts tax prompted immediate litigation, and Washington’s expansion of its sales tax to advertising services has already been challenged under ITFA. Illinois recently enacted its own targeted advertising tax and should expect to face a similar challenge.

    Any state that follows Maryland’s lead by taxing internet advertising while excluding comparable advertising delivered through other channels should assume that it is also choosing litigation – and should be prepared to defend that choice in court.

    Authors

    Stephen P. Kranz

    Partner

    Washington, DC

    Mark Nebergall

    Counsel

    Washington, DC

    Jonathan C. Hague

    Associate

    Austin

    More insights
    Endnotes

  • Beyond cost-cutting: How health systems can accelerate through budget crises

    Beyond cost-cutting: How health systems can accelerate through budget crises

    ARTICLE

    Beyond cost-cutting: How health systems can accelerate through budget crises

    Jul 27, 2026

    Read time: 11 min

    Overview

    Many hospitals and health systems across the United States are facing a systemic financial crisis, and operational efficiency or cost-cutting measures alone won’t be enough to keep the lights on. Rising costs are outpacing reimbursement rates, workforce shortages persist, research funding has been cut, recent federal legislation such as the One Big Beautiful Bill (OBBB) has introduced looming financial implications – and the list goes on. The stakes have never been higher.

    Based on Congressional Budget Office projections, the OBBB is expected to eliminate more than 10.5 million people from Medicaid by 2034, cutting federal spending on Medicaid and CHIP by more than $1 trillion. Safety net hospitals are the most exposed, but the impact will extend to virtually any health system that accepts Medicaid. Hundreds of rural hospitals are at risk of closure within six to seven years, as they accumulate losses from delivering critical emergency and primary care services. And in 2025, the US National Institutes of Health terminated more than 1,100 grants to academic centers, amounting to a $2 billion research funding cut.

    Against this backdrop, healthcare leaders must make strategic business decisions with fewer resources and greater uncertainty.

    To fill widening budget gaps, accelerate growth, and advance patient care, forward-thinking leaders are taking two complementary, high-impact routes: Innovative operational and physician alignment strategies (which incentivize value-based care), and creative financing.

    Route one: Operational and alignment strategies to improve margins

    Many healthcare leaders believe that regulatory constraints – particularly the physician self-referral law (Stark Law) and the Anti-Kickback Statute (AKS) – inhibit innovative arrangements that further care outcomes and increase physician alignment, but that assumption is increasingly outdated. Recent updates, particularly new exceptions and safe harbors to both the Stark Law and AKS, have opened compliant pathways that allow health systems to align physicians with organizational goals and patient outcomes, foster stronger care coordination, improve in-network retention, and strengthen long-term financial outlook.

    Physician alignment, new compensation models, and value-based care arrangements

    Meaningful improvements in physician alignment aren’t necessarily expensive, although arrangements must be implemented carefully to ensure legal compliance.

    One of the most accessible starting points is reviewing and updating existing physician arrangements. In this case, your organization can use new regulatory pathways that offer a way to advance value-based care while improving network integrity and physician alignment.

    These pathways exist because the Centers for Medicare and Medicaid Services (CMS) and other payors are increasingly interested in paying for care that achieves the “triple aim” – improved population health, improved quality of care and patient experience, and lower cost of care. To further these aims, CMS and the Office of Inspector General (OIG) have created new Stark Law exceptions and AKS safe harbors that remove traditional barriers to innovative physician compensation arrangements.

    For instance, unlike most previous Stark Law exceptions, if relevant criteria are met, the updated exceptions allow a physician’s compensation to take into account the volume or value of their referrals and not necessarily be commensurate with fair market value (two key tenets of most exceptions that can stifle compensation arrangements that incentivize quality care). Updates to the personal services and management contracts safe harbor extend protection to certain outcomes-based payment arrangements, providing additional flexibility in structuring physician compensation.

    The updated exceptions and safe harbors can apply to traditional fee-for-service arrangements and do not require health systems to assume risk.

    Site-of-care optimization, ASCs, and joint ventures

    Another pivot health systems should consider involves outpatient-centric care delivery – a shift made more urgent by the move toward site-neutral payment policies. As CMS aims to equalize reimbursement for services regardless of where they are delivered, moving toward lower-cost outpatient care settings puts health systems at a disadvantage unless they implement new outpatient and ambulatory care delivery strategies.

    One option for making this pivot: joint ventures and partnership structures that move care to lower-cost settings while providing physicians with meaningful financial participation. This means exploring ambulatory surgery center (ASC) joint ventures with physicians, as well as clinic-based structures that give physicians equity, capital, or profit-sharing interests. Allowing physicians to hold a genuine stake deepens alignment, strengthens network integrity, and repositions care delivery strategy to be more resilient in a site-neutral payment environment.

    Route two: Creative financing to unlock capital

    In addition to reorganizing on the medical side, physician alignment, and other options that your organization may already be considering, for the right institution with the right portfolio of assets, there are many out-of-the-box ideas and financial levers to pull.

    Monetizing assets

    The range of assets that hospitals and university systems can consider for financing is broader than many leaders recognize. Options include monetizing intellectual property, considering future flow deals for operating businesses, and separating and optimizing real estate holdings. All represent viable mechanisms for unlocking enterprise value, depending on your institution’s asset profile.

    In the case of academic medical centers, for example, the intersection of university IP, brand rights, and research capabilities creates additional opportunities. One is spinning out business assets with associated IP. Another is pursuing structures such as special purpose acquisition companies (SPACs) or initial public offerings (IPOs) of those businesses to raise capital independently. Some universities have explored using alumni networks to fund venture capital vehicles as a substitute for lost research funding. Others have even considered whether they could securitize full-pay student tuition.

    De-risking through capital markets

    Beyond outright monetization, your organization can use capital markets structures to reduce concentration risk. Selling economic interests in large, centralized cash flows to institutional investors – including hedge funds, alternative asset managers, mutual funds, and insurance companies, all of which have significant appetite for yield product – allows organizations to de-risk their balance sheets while simultaneously raising capital.

    For institutions that are structurally complex, such as academic medical centers where the credit rating of the medical system and the university differ materially, separating entities or restructuring the capital structure can improve financing terms and access to capital markets.

    None of these ideas are radical. The healthcare organizations that are changing their financial strategies and reorganizing how they fund themselves are borrowing techniques from other industries that faced similar challenges and applying them in new ways.

    Over the years, we’ve worked with a number of health systems around the country to create custom solutions designed around utilizing existing revenue-producing assets to fill budget gaps. Every institution has different assets and goals, but these are a few of the real-world successes we’ve had in unlocking enterprise value for healthcare systems:

    Vanderbilt University monetized payments from the Vanderbilt University Medical Center after legally and financially separating from the University, de-risking concentration risk and raising significant funding.

    An academic medical center sold its share of the royalty rights for an oncology blockbuster drug in a deal that helped to fund ongoing innovation.

    A large healthcare provider spun off some of its real estate holdings and advisory capabilities into a standalone consulting business that performs similar functions for a multitude of institutions.

    Now is the time for bold moves

    The financial pressures facing hospitals and health systems today are significant. Yet this moment also presents an opportunity to think creatively and act decisively.

    The blocking and tackling of physician financial relationships, including updated contracts, value-based incentive structures, and outpatient joint ventures, can be accomplished without large capital outlays and can meaningfully improve alignment and network integrity. At the same time, capital markets offer a range of tools that health systems are only beginning to explore, providing a path to unlock yet-unrealized value from existing assets.

    The way forward is not one-size-fits-all. Every organization requires a customized plan that accounts for its unique structure, assets, and regulatory considerations. But the organizations that will emerge strongest from the current environment are those open to pursuing both paths. The strategies are complementary, and the time to act is now.

    Contact your McDermott lawyer or the authors to learn more about engaging our health and life sciences crisis task force, which brings together members of our world-class healthcare and financial services teams to help you identify creative budget solutions.

    Authors

    Ira Schacter

    Partner

    New York – One Vanderbilt Avenue

    Nicholas F. Alarif

    Partner

    Washington, DC

    More insights

  • Specificity matters: Eighth Circuit rejects broad trade secret claims

    Specificity matters: Eighth Circuit rejects broad trade secret claims

    ARTICLE

    Specificity matters: Eighth Circuit rejects broad trade secret claims

    Jul 23, 2026

    Read time: 4 min

    Key takeaways
    Overview

    The US Court of Appeals for the Eighth Circuit affirmed a district court’s summary judgment against a trade secret plaintiff, finding that the plaintiff’s broad descriptions of confidential business information failed to identify its alleged trade secrets with sufficient specificity. Wilbur-Ellis Company v. Gompert, et al., Case Nos. 25-1577; -1682 (8th Cir. July 7, 2026) (Shepard, Erickson, Grasz, JJ.)

    Wilbur-Ellis, an international marketer and distributor of agricultural products, specialty chemicals, and ingredients, sued four former employees after they left to join competitor J.R. Simplot Company, alleging breach of the duty of loyalty, trade secret misappropriation under the Defend Trade Secrets Act (DTSA) and the Nebraska Trade Secrets Act (NTSA), and tortious interference with business relationships. During discovery, the district court denied Wilbur-Ellis’s requests to compel discovery from both Simplot and the former employees, concluding that Wilbur-Ellis had not identified its alleged trade secrets with sufficient specificity to justify the requested discovery. After denying Wilbur-Ellis’s request to delay summary judgment pending additional discovery, the district court granted summary judgment to the former employees on the trade secret and tortious interference claims and on most of the duty-of-loyalty claims. Wilbur-Ellis appealed.

    Discovery orders affirmed

    Wilbur-Ellis argued that the district court improperly prevented it from obtaining discovery from Simplot by requiring it to identify its alleged trade secrets with greater specificity before permitting third-party discovery.

    The Eighth Circuit disagreed, finding that the district court did not abuse its discretion in denying Wilbur-Ellis’s motion to compel. The Eighth Circuit noted that the district court had identified several concerns, including that Wilbur-Ellis’s trade secret disclosure was extremely broad, appeared to treat nearly everything the former employees encountered as a trade secret, and raised concerns that the requested third-party discovery would amount to a fishing expedition. The Court emphasized that Wilbur-Ellis did not dispute those findings on appeal or that it had sought third-party discovery before exhausting discovery from the former employees.

    Trade secret claims fail for lack of specificity and evidence

    Wilbur-Ellis also argued that the district court improperly granted summary judgment on its DTSA and NTSA claims. The Eighth Circuit disagreed, concluding that Wilbur-Ellis failed to present sufficient evidence that it possessed protectable trade secrets or that the defendants misappropriated them. The Court explained that Wilbur-Ellis relied on broad descriptions of categories of information – such as customer information, financial information, and business strategy – without identifying the specific trade secrets allegedly taken, who misappropriated them, or how they were misappropriated. The Court further found that, although Wilbur-Ellis identified its password-protected SeedWare database as confidential, it failed to produce evidence that the defendants improperly acquired, disclosed, or used any information contained in the database. Because Wilbur-Ellis failed to connect its allegations to specific trade secrets or admissible evidence of misappropriation, the Court found summary judgment was appropriate.

    Duty of loyalty claims

    Wilbur-Ellis next argued that the district court improperly granted summary judgment on its breach of the duty of loyalty claims. The Eighth Circuit disagreed, finding that Wilbur-Ellis failed to present admissible evidence that the former employees engaged in conduct prohibited under Nebraska law. The Court explained that employees are generally free to prepare to compete with their employer, including accepting employment with a competitor, absent evidence that they misappropriated trade secrets, solicited customers or employees while still employed, or otherwise substantially hindered the employer’s business. The Court affirmed summary judgment on the duty of loyalty claims, finding that Wilbur-Ellis relied primarily on speculation regarding the employees’ coordinated resignations, alleged solicitation of coworkers and customers, and resetting of company devices, rather than specific, admissible evidence demonstrating disloyal conduct or resulting harm.

    Tortious interference claim

    Wilbur-Ellis also challenged the district court’s grant of summary judgment on its tortious interference claim. The district court found that Wilbur-Ellis relied primarily on unsupported allegations and hearsay, rather than admissible evidence showing that any specific defendant committed an act of interference or that any such conduct caused Wilbur-Ellis’s alleged damages. The Eighth Circuit affirmed, concluding that Wilbur-Ellis failed to present evidence that the former employees intentionally and unjustifiably interfered with their business relationships.

    Authors

    Jodi Benassi

    Partner

    San Francisco

    More insights
    Endnotes

  • A $40 million jury instruction error sends trade secret dispute back to trial

    A $40 million jury instruction error sends trade secret dispute back to trial

    ARTICLE

    A $40 million jury instruction error sends trade secret dispute back to trial

    Jul 23, 2026

    Read time: 5 min

    Key takeaways
    Overview

    The US Court of Appeals for the Ninth Circuit reversed a jury damages award, a permanent injunction, and an attorneys’ fee award in a trade secret misappropriation case, finding that the district court improperly instructed the jury on which party bore the burden of proving whether the asserted trade secrets were “readily ascertainable through proper means.” Comet Technologies USA, Inc. et al. v. XP Power, LLC, Case Nos. 23-15601; 25-15709; 25-745 (9th Cir. July 14, 2026) (Hamilton, Nelson, Bumatay, JJ.) (Bumatay, dissenting)

    Comet Technologies, a Swiss-based leader in x-ray and radio-frequency products, sued US-based competitor XP Power after three former Comet engineers left to join XP, allegedly bringing thousands of confidential documents relating to Comet’s radio-frequency power technologies, product designs, and research and development. Comet asserted claims under the federal Defend Trade Secrets Act (DTSA) and California’s Uniform Trade Secrets Act (CUTSA).

    Before trial, Comet narrowed its case to five alleged trade secrets and voluntarily dismissed its CUTSA claims, leaving only its DTSA claims. The parties addressed the effect of that dismissal on the jury instructions, with XP requesting that the burden of proving lack of ready ascertainability be shifted to Comet to conform to the DTSA while Comet argued that the instruction should be removed entirely. The district court rejected both requests without an on-the-record explanation and left in Instruction 20, which told the jury that XP was not liable for misappropriation if XP proved by a preponderance of the evidence that the alleged trade secrets were readily ascertainable by proper means, meaning they could be lawfully “obtained, discovered, developed, reverse-engineered, or compiled without significant difficulty, effort, or expense.”

    The jury found that XP misappropriated three of the five trade secrets and awarded Comet $20 million in compensatory damages and $20 million in exemplary damages. The district court also entered a permanent injunction and awarded more than $17 million in attorneys’ fees. XP appealed.

    Erroneous jury instruction: “Readily ascertainable by proper means”

    XP argued that the district court improperly instructed the jury that XP bore the burden of proving that Comet’s alleged trade secrets were “readily ascertainable by proper means.” Comet argued that XP invited the instructional error by requesting that the challenged instruction be given to the jury and, alternatively, that any error was harmless because the instructions were accurate as a whole, they correctly stated the law, and the evidence overwhelmingly established that Comet’s trade secrets were not readily ascertainable through proper means.

    The Ninth Circuit agreed with XP, explaining that under the DTSA, lack of ready ascertainability is an element of Comet’s DTSA claim – not an affirmative defense – and, therefore, Comet bore the burden of proof. The Court rejected Comet’s invited-error argument, finding that XP timely objected after Comet dismissed its CUTSA claims and correctly argued that, under the DTSA, Comet – not XP – bore the burden of proving that the alleged trade secrets were not readily ascertainable through proper means.

    The Ninth Circuit also rejected Comet’s harmless-error argument. The Court explained that the erroneous instruction affected an essential element of the DTSA claims and that the parties presented conflicting expert testimony regarding whether aspects of the alleged trade secrets could have been reverse-engineered or derived from public sources. Because those factual disputes were central to determining whether the information qualified as trade secrets under the DTSA, the Court could not conclude that a properly instructed jury likely would have reached the same verdict or awarded the same damages.

    Damages

    XP also challenged the jury’s award of unjust enrichment damages, which were measured by the research and development costs XP allegedly avoided by misappropriating Comet’s trade secrets, rather than developing the technology independently. Although the Ninth Circuit did not decide whether that damages theory was legally proper because it ordered a new trial, the Court explained that the erroneous jury instruction was not harmless, in part because it may have affected the damages award. Comet’s damages expert calculated unjust enrichment damages based on XP’s avoided development costs, assuming that all the information comprising the asserted trade secrets was protectable. Because the jury was improperly instructed on whether certain aspects of the alleged trade secrets were readily ascertainable through proper means, the Court could not determine whether a properly instructed jury would have found all the asserted information protectable or awarded the same amount of damages. The Court vacated the entire damages award and remanded for a new trial.

    In a separate concurrence, Judge David F. Hamilton addressed an issue likely to arise on remand, explaining that he would permit both avoided-cost unjust enrichment damages and prospective injunctive relief under the DTSA because the remedies compensate for different harms.

    Practice note: The decision highlights the importance of revisiting jury instructions whenever claims are dismissed or narrowed before trial. The DTSA places the burden on the plaintiff to prove that alleged trade secrets are not readily ascertainable through proper means. Where a case proceeds solely under the DTSA, courts must ensure that jury instructions accurately allocate that burden, as an erroneous burden-shifting instruction on an essential element of a trade secret claim may require a new trial, even after a substantial jury verdict.

    Authors

    Jodi Benassi

    Partner

    San Francisco

    More insights
    Endnotes

  • Building the next generation of behavioral health platforms

    Building the next generation of behavioral health platforms

    ARTICLE

    Building the next generation of behavioral health platforms

    Jul 22, 2026

    Read time: 9 min

    Key takeaways
    Overview

    The behavioral health sector represents one of healthcare’s most distinct platform-building opportunities.

    The Substance Abuse and Mental Health Services Administration (SAMHSA) reports that 61.5 million US adults experienced a mental illness in 2024, yet only about half received treatment. This pervasive gap between need and access is driving innovation and investment across the sector, including how behavioral health providers are approaching growth and choosing pathways to scalability.

    To reap the benefits, behavioral health operators are seeking out specialization, including a more comprehensive approach to pre- and post-diagnosis support and education. The organizations that are building focused clinical platforms, pursuing more integrated models of care, and investing in capabilities to support more complex operations are the ones staying ahead of the curve.

    Discussions at McDermott HealthEx 2026 explored how these shifts are influencing investment activity and strategic dealmaking across the behavioral health landscape, including:

    behavorial health investment and growth over next twelve to twenty four months
    In depth

    Bullish market outlook amidst regulatory shifts

    Poll responses reflected strong optimism about the sector. Panelists expressed similar confidence in behavioral health’s trajectory, with one noting that we’ll likely see a “cascade or almost an avalanche of growth” in the coming years. This tremendous opportunity is driven by pent-up demand and persistent gaps in care access, particularly in rural and underserved communities where behavioral health providers and inpatient capacity are limited.

    At the same time, discussions focused on how Medicaid coverage reductions and broader agency changes stand to strain providers that depend heavily on government reimbursement.

    The One Big Beautiful Bill Act (OBBBA), for example, introduces new operational considerations for behavioral health providers with significant Medicaid exposure. Although individuals with substance use disorders and certain mental health conditions are exempt from the law’s community engagement requirements, recent Centers for Medicare and Medicaid Services (CMS) guidance places responsibility on states to define qualifying conditions and establish verification processes, creating uncertainty around implementation and patient access.

    To help combat these losses, state innovation efforts, carve-outs, parity enforcement, and value-based care models can create new avenues for growth and better access.

    Capital is flowing, but the market is becoming more specialized

    Panelists emphasized that behavioral health is no longer a single investment category, but a collection of distinct subsectors, including:

    • Autism support services
    • Outpatient mental health treatment
    • Substance use and addiction treatment
    • Intellectual and developmental disability (IDD) services
    • Other specialty categories (e.g., eating disorders)

    Each subsector comes with its own workforce, reimbursement, and operating requirements. Investors are evaluating these differences more closely and in consideration with longer-term goals and financing strategies.[5.1][5.2] As transaction timelines lengthen and underwriting becomes more rigorous, buyers are placing greater emphasis on clinical quality, workforce stability, and the operational capabilities required to support long-term growth.

    The autism market reflects that shift, with one panelist describing a growing “flight to quality” focused on high-performing providers. Investors are placing a premium on providers that have the infrastructure to grow, “not just to add more sites and more clients,” but to sustain quality as they scale. Another added that organizations with strong operating foundations are likely to emerge stronger as the market continues to consolidate.

    Specialization is creating new opportunities

    Specialization matters in behavioral health care delivery. Providers are building organizations and offerings around specific patient populations and treatment approaches rather than broad service portfolios. This focused approach helps with patient recruitment, referral development, and achieving positive clinical outcomes, but only when supported by the right infrastructure and support services.

    Autism services is one are a where more specialized expertise can support both growth and better outcomes. Providers building treatment around an individual’s specific needs and circumstances – rather than around standardized measures like number of therapy hours per week – are better positioned to demonstrate clinical impact and meaningfully engage payors in value-oriented conversations. Having well-established clinical protocols and more comprehensive quality measurement frameworks can help organizations scale while maintaining the characteristics that made them successful in the first place.

    Interventional psychiatry (e.g., TMS, esketamine, and infusion-based therapies) is also on the rise. While increasingly being used in outpatient behavioral health platforms, it is still seeing uneven in-patient adoption, given both limited reimbursement pathways and patient awareness.

    Organizations that invest now in building physician expertise, intake infrastructure, and referral relationships for these newer modalities are likely to be better positioned as the market matures – particularly if reimbursement coverage expands and new indications receive regulatory clearance.

    Reimbursement reform is reshaping behavioral health’s future

    McDermott HealthEx poll respondents unanimously identified reimbursement reform – including changes to payment models, CPT codes, and provider eligibility – as the factor most likely to reshape behavioral health in the near term:

    reimbursement reform for emerging protcols

    Panelists noted that expanding reimbursement for integrated care models, telebehavioral health, and emerging treatment protocols will help unlock new growth opportunities by allowing providers to deliver care more efficiently, broaden the types of clinicians who can practice at the top of their licenses, and make innovative services economically sustainable at scale.

    State investments in crisis infrastructure, community-based care, and behavioral health redesign are also creating additional avenues for reimbursement and expansion, if they’re able to produce measurable results. As one panel discussed, standing up community-based crisis programs – particularly those focused on mobile response and stabilization services (MRSS) – can demonstrate meaningful reductions in emergency department utilization and downstream system involvement when replicated across a state.

    Where these outcomes can be documented and sustained, and presented as a “demonstrated business case” to both CMS and SAMHSA, as one panelist detailed, they can open new reimbursement pathways and create further expansion opportunities for providers.

    Growth requires stronger foundations and better patient access

    The greatest constraint on behavioral health growth is capacity. Demand regularly exceeds available service providers, creating opportunities for providers that can expand access and provide more complete support and education, especially in growing needs bases.

    In autism care services, families in some markets may wait 12 months or longer for a diagnosis and subsequent treatment, not including the time-intensive evaluations that precede that diagnosis. Families and patients also need meaningful support to understand that diagnosis, its potential impact, and available treatment options.

    Whether with autism or another complex behavioral health condition, providers that address both the diagnostic and the post-diagnosis education and support gap are solving a more complete version of the access problem, which requires more than a steady opening of new sites of care to solve. This more comprehensive approach requires well-established clinician pipelines, better clinical oversight, and more extensive care delivery models that can be replicated across markets. Providers that build those capabilities can turn access challenges into sustainable growth opportunities.

    Managed care organizations are also playing a larger role in defining network requirements, quality expectations, and reimbursement structures. Providers that can improve care access by working collaboratively in their markets – while operating effectively in performance-oriented models – will stand a better chance of growing long-term and differentiating themselves in a crowded market.

    Technology is enabling specialization and better integration

    Unlike more mature healthcare segments, many behavioral health organizations still have substantial opportunities to strengthen core infrastructure, standardize workflows, and invest in scalable platforms in support of long-term growth and increased attractiveness to potential buyers.

    One panel described behavioral health’s relatively immature technology infrastructure, electronic medical records (EMR) capabilities, and operating systems as a source of significant upside rather than a disadvantage, given the ability to create and customize solutions as needed. At the same time, panelists emphasized that strong technology foundations – from EMR integration and revenue cycle capabilities to data and outcomes measurement – are becoming increasingly important differentiators as investors place greater emphasis on operational rigor and demonstrated growth capabilities.

    In autism services, panelists highlighted how AI is supporting earlier diagnoses, creating greater consistency in clinical decision-making, and helping clinicians serve more patients without sacrificing quality. Technology is most valuable when it strengthens, not replaces, the operational and clinical foundations that differentiate high-performing organizations.

    Integrated care is reshaping behavioral health delivery

    Integration is a strategic priority as organizations seek to improve care quality, enable more seamless patient engagement, and create more coordinated experiences for patients with complex behavioral health and comorbid conditions. Behavioral health providers with care models that extend beyond individual encounters are gaining more market attention.

    Substance use disorder (SUD) treatment presents immense opportunities for organizations looking to connect treatment needs, recovery support, and ongoing rehabilitation. Interest is growing in longitudinal care models that maintain engagement over time and provide greater visibility into patient progress. These approaches align with broader efforts to improve outcomes while reducing fragmentation.

    As one panelist described, their organization’s SUD care model has a three-part clinical framework: outpatient counseling at the core, wrapped with medical care from physicians and nurse practitioners, anchored by a third component of recovery support services addressing social determinants of health. The combination of all three – under one roof, and simultaneously for each patient – is what drives differentiated outcomes.

    The shift is influencing payor strategy as well. There is a growing demand for measurable outcomes and performance-based reimbursement. Organizations pursuing these arrangements will need to be able to track outcomes consistently and demonstrate clinical impact.

    Looking ahead

    Growth in behavioral health won’t come without friction. Workforce shortages are creating obstacles for nearly every segment. Regulatory complexity and reimbursement variability remain unresolved. The gap between what patients need and what the system delivers hasn’t closed.

    Some behavioral health organizations see partnerships as the path to scale and new operational capabilities, while others are evaluating new market opportunities and expanding service offerings in search of a competitive advantage.

    The behavioral health landscape has transformed, and organizations need to find a new way forward. The platforms best positioned to scale and lead are the ones improving care access, meaningfully impacting outcomes, and turning a typically fragmented collection of services into a longitudinal, integrated care experience.

    Authors
    More insights
    Endnotes

  • Trending in Telehealth: June 2026

    Trending in Telehealth: June 2026

    ARTICLE

    Trending in Telehealth: June 2026

    Jul 21, 2026

    Read time: 5 min

    Key takeaways
    Overview

    Trending in Telehealth highlights monthly state legislative and regulatory developments that impact the healthcare providers, telehealth and digital health companies, pharmacists, and technology companies that deliver and facilitate the delivery of virtual care.

    Trending in June:

    • Telehealth reimbursement and payment parity
    • Licensure and cross-state practice
    • Telehealth practice-specific standards and documentation requirements
    • Expansion of telehealth across specialties and e-prescribing

    A CLOSER LOOK

    Proposed legislation and rulemaking:

    • Iowa’s Board of Optometry proposed rule 481-762.9. If adopted, it would establish the standard of care requirements for teleoptometry, clarify when an optometrist-patient relationship is established through telehealth, and prohibit the use of telemedicine if, consistent with the standard of care, an in-person examination would be required to produce an informed diagnosis.
    • West Virginia’s Board of Medicine proposed rule 8537 seeking to establish the regulatory framework for the licensure and regulation of genetic counselors in West Virginia, including telehealth practice standards. The rule would define the telemedicine modalities that a genetic counselor may use to establish a patient relationship and would establish the same standard of care for telemedicine services as required for in-person services.
    • Vermont’s Office of Professional Regulation proposed rule 26P013, which would govern the licensing and registration of out-of-state healthcare professionals providing telehealth-only services to Vermont patients. Currently, healthcare providers who are not licensed in Vermont are not required to pay fees, but this rule would establish an application and renewal fee requirement in order to provide telehealth services to Vermont patients.
    • Texas’s Board of Pharmacy proposed rule 49743, which would establish documentation and record retention requirements for telehealth services provided by a pharmacist in Texas.
    • California AB 225 passed one chamber and aims to prevent billing for or collection of facility fees for preventive care telehealth services. The bill would impose notification requirements regarding facility fees and penalties for violations, and would prohibit health insurers from passing facility fees on to enrollees.

    Finalized legislation and rulemaking:

    • Rhode Island enacted SB 3180, expanding veterinary telemedicine authority by allowing veterinarians in Rhode Island to establish provider-patient relationships using . Previously, telehealth was limited to animals with an existing provider-patient relationship. In-person examinations are required to renew a prescription that was previously renewed twice based only on virtual examinations. Controlled substances may not be prescribed without an in-person examination.
    • Florida final rule 52933 was published, establishing requirements for clinical social work, marriage and family therapy, and mental health counseling intern supervision, including hour thresholds, the use of in-person versus electronic methods, telehealth protocols, and the distinction between individual and group supervision. Face-to-face psychotherapy is defined to include electronic methods as long as certain requirements are met, including that the provider maintains a written telehealth protocol and safety plan.
    • Alaska’s second chamber passed HB 14, which would require a healthcare insurer to reimburse a provider for healthcare services, including behavioral health services, provided through telehealth on the same basis and at least at the same rate as for comparable healthcare services provided in person. The bill allows insurers to implement a geographic pay differential to reimburse out-of-state providers.
    • Both chambers of the Illinois legislature passed SB 3211, establishing protocols for diagnosis and care delivery using telehealth systems by licensed dentists and requiring certain dental services to be provided in person. A synchronous exam is required prior to the processing of x-rays as ordered by a supervising dentist, and local anesthetics may not be used during certain procedures provided in a teledentistry service by a dental hygienist.
    • West Virginia enacted HB 5458, which allows a genetic counselor to provide telehealth services and gives the West Virginia Board of Medicine authority to establish the standard of care for the provision of genetic counseling via telehealth

    Why it matters:

    • States are establishing more detailed telehealth practice and compliance requirements. Legislative and regulatory activity reflects a growing focus on informed consent, documentation, supervision, and the standards governing the formation of provider-patient relationships in virtual care settings.
    • Telehealth expansion is increasingly paired with specialty-specific standards of care. States are expanding telehealth authority across a broader range of professions while imposing requirements related to clinical appropriateness, prescribing, modality use, and circumstances that continue to require in-person services.
    • Reimbursement and cross-state practice remain significant areas of policy development. Lawmakers and regulators continue to evaluate payment parity, patient cost protection, and licensure frameworks for out-of-state providers, reflecting efforts to expand access to care while maintaining regulatory oversight and accountability.

    Telehealth is an important development in care delivery, but the regulatory patchwork is complicated. The McDermott Will & Schulte digital health team works alongside the industry’s leading providers, payors, and technology innovators to help them enter new markets, break down barriers to delivering accessible care, and mitigate enforcement risk through proactive compliance.

    Authors

    Stacey L. Callaghan

    Partner

    Chicago

    Amanda Enyeart

    Partner

    Chicago

    Olivia Andrews

    Associate

    New York – One Vanderbilt Avenue

    More insights
    Endnotes

  • Latest tax updates: IRS launches automatic penalty relief program and court invalidates GILTI rule

    Latest tax updates: IRS launches automatic penalty relief program and court invalidates GILTI rule

    ARTICLE

    Latest tax updates: IRS launches automatic penalty relief program and court invalidates GILTI rule

    Jul 20, 2026

    Read time: 5 min

    Several notable tax developments have recently emerged, including the Internal Revenue Service’s (IRS) new automatic penalty relief program and a taxpayer-favorable court decision that struck down a key global intangible low-taxed income (GILTI) regulation. The US Department of the Treasury and the IRS also finalized guidance on life insurance contract transactions and issued updates affecting various energy-related tax credits and reporting obligations.

    Updates from the IRS and Treasury

    July 8, 2026: The IRS announced a new Automatic Exemption from Penalty (AEP) program, a systemic administrative relief program expected to begin this summer. AEP will replace the long-standing First Time Abate administrative relief process and apply to eligible original returns beginning with tax year 2025 and 2026 quarterly returns. Taxpayers generally qualify if IRS records show timely filing and payment for the prior three years or 12 consecutive quarters for quarterly filers. For qualifying taxpayers, the IRS will not assess failure-to-file, failure-to-pay, or failure-to-deposit penalties during processing.

    AEP will apply to certain business and employment tax returns, including Forms 1065, 1120, 940, 941, 943, 944, 945, and CT-1. During the transition period, some qualifying taxpayers may still receive penalty notices for eligible 2025 tax year and 2026 quarterly returns. Taxpayers who believe they qualify may contact the IRS to request First Time Abate. AEP will replace First Time Abate for eligible returns with original due dates on or after January 1, 2027.

    July 9, 2026: The Treasury and the IRS issued final regulations in Treasury Decision 10052, addressing the application of the transfer-for-value rules and related information reporting requirements under Internal Revenue Code (Code) §§ 101 and 6050Y to § 1035 exchanges of life insurance contracts and certain acquisitions of life insurance contracts in corporate reorganizations. The final regulations affect parties involved in these life insurance contract transactions, including with respect to reportable death benefits.

    The final regulations generally retain the approach of the 2023 proposed regulations: treating a § 1035 exchange, standing alone, not as a transfer of the newly issued life insurance contract. The final regulations also reverse the broader treatment reflected in the 2019 final regulations while preserving rules intended to track contracts that previously were transferred in reportable policy sales. The Treasury and the IRS also declined to adopt certain proposed information return filing requirements for old and new issuers in § 1035 exchanges of reportable policy sale contracts, concluding that compliance goals can be addressed through the old issuer’s Form 1099-R reporting and related information exchange between issuers.

    July 9, 2026: The IRS published Internal Revenue Bulletin 2026-29, which includes several items relevant to energy, fuel, chemicals, and importer taxpayers.

    Notice 2026-41 publishes the 2026 inflation adjustment factors and applicable amounts for the Code § 45U zero-emission nuclear power production credit, the Code § 45V clean hydrogen production credit, and the Code § 45Z clean fuel production credit. For 2026, the notice provides, among other amounts, a § 45V inflation-adjusted applicable amount of $0.656 before applying the lifecycle greenhouse gas emissions percentage, and § 45Z amounts of 22 cents and $1.09 for transportation fuel produced and sold in calendar year 2026.

    Notice 2026-42 provides the applicable reference price and credit amount for qualified natural gas production from qualified marginal wells for taxable years beginning in calendar year 2026. The notice sets the reference price at $2.20 per Mcf and the credit amount at $0.81 per Mcf. Notice 2026-43 adds two substances – chloro-isobutene-isoprene rubber and ethylene-propylene-dicyclopentadiene rubber – to the list of taxable substances for purposes of the Superfund chemical substances tax under Code § 4671, effective October 1, 2026, for tax purposes and April 1, 2023, for certain refund claim purposes.

    Recent court decision

    July 2, 2026: In Keysight Technologies Inc. & Subsidiaries v. United States, the US Court of Federal Claims handed taxpayers a significant post-Loper Bright win, holding that the Treasury lacked authority to issue Treas. Reg. § 1.951A-2(c)(5), the GILTI “disqualified basis” rule that denied certain amortization and depreciation deductions arising from gap-period related-party transfers. The Court rejected the government’s position that Section 7805(a)’s general “needful rules” authority, either standing alone or paired with other statutory delegations, allowed the Treasury to rewrite the statutory allocation rules to prevent what the Treasury viewed as an unintended fiscal-year taxpayer benefit.

    The decision is notable because it is another concrete example of how Loper Bright is reshaping how a court evaluates the validity of a regulation: statutory ambiguity is no longer enough for the Treasury to require courts to respect its interpretation. The Court was blunt that allowing the Treasury to define statutory terms it views as ambiguous, without a specific congressional grant of authority, would be exactly the kind of agency overreach Loper Bright was meant to stop. Taxpayers with affected GILTI computations should review return positions and consider possible protective claims pending likely further litigation by the government to try and redeem the regulation.

    In depth
    Authors

    Edward L. Froelich

    Counsel

    Washington, DC

    Akiva B. Ungar

    Associate

    Chicago

    More insights
    Endnotes

  • Navigating Europe’s defense investment landscape: Key takeaways

    Navigating Europe’s defense investment landscape: Key takeaways

    ARTICLE

    Navigating Europe’s defense investment landscape: Key takeaways

    July 20, 2026

    Read time: 7 min

    Overview

    Europe’s defense sector is undergoing a profound transformation driven by heightened geopolitical tensions, evolving security requirements, and unprecedented public investment commitments. The commitment by NATO nations to increase defense-related spending to 5% of GDP is creating one of the largest industrial investment opportunities in recent decades, extending beyond military equipment into critical infrastructure, manufacturing capacity, logistics, and technology development.

    In our latest webinar, we took a look at the developments and trends driving progress and innovation in the sector, with a particular eye to what is most note-worthy and interesting for investors.

    Read on for our key takeaways:

    In depth

    Defense investment is accelerating

    European governments are making unprecedented long-term commitments to defense and security spending, creating opportunities across manufacturing, critical infrastructure and advanced technologies. Initiatives such as the ReArm Europe Plan are designed to strengthen Europe’s defense industrial base and strategic resilience, while recent conflicts have reinforced the importance of resilient supply chains and scalable production.

    Key growth areas include:

    • Artificial intelligence and autonomous systems.
    • Advanced manufacturing, software and space technologies.
    • Critical infrastructure and supply chain resilience.

    Innovation is reshaping the market

    Rapid technological advancement is attracting significant venture capital and private equity investment, particularly in AI, autonomous systems and software-enabled capabilities. Established defense contractors are increasingly partnering with emerging technology companies through joint ventures, strategic partnerships and acquisitions to combine innovation with industrial scale. As discussed during the webinar, consolidation is expected to accelerate as companies seek to strengthen capabilities and respond to evolving procurement requirements.

    Regulation is evolving alongside investment

    Europe is adapting its regulatory framework to strengthen strategic autonomy and defense readiness. Recent initiatives, including the Defence Readiness Omnibus package and Defence Readiness Roadmap 2030, demonstrate a broader shift towards supporting industrial resilience and European defense capabilities. Competition policy is also evolving, with the European Commission’s draft revised EU Merger Guidelines recognising that scale-enhancing transactions may contribute to defense readiness and security of supply. As a result, consolidation is becoming an increasingly important feature of the sector.

    National security is becoming central to transactions

    Foreign investment screening is playing an increasingly significant role in cross-border transactions involving defense, dual-use technologies and critical infrastructure. Reforms to the EU Foreign Direct Investment Screening Regulation will expand mandatory screening across strategic sectors, increase scrutiny of indirect ownership structures and strengthen cooperation between Member States.* Regulatory approvals are therefore becoming an increasingly important consideration for transaction timing and execution.

    Export controls are now a strategic investment issue

    Export controls and sanctions have evolved beyond traditional compliance obligations and increasingly influence valuation, transaction timelines, supply chain decisions and exit opportunities. Investors should assess export controls alongside foreign investment screening and competition issues from the outset, particularly where businesses develop or use strategic technologies. Regulators are also placing greater emphasis on software, technical know-how and technology transfers, rather than physical exports alone.

    Successful due diligence should consider:

    • The technologies and products subject to export controls, including dual-use items.
    • The interaction between EU, UK and US regulatory regimes.
    • Licensing requirements that could affect future operations or exit options.

    Early planning creates value

    Competition law, foreign investment screening, export controls and sanctions increasingly operate together around the same strategic technologies. Businesses with robust governance, licensing strategies and compliance frameworks are better positioned to manage regulatory scrutiny, reduce execution risk and maximise long-term value. An integrated approach to regulatory due diligence can improve deal certainty and help avoid costly delays later in the transaction process.

    Conclusion

    As Europe continues to strengthen its defense capabilities, investors will need to balance significant commercial opportunities with an increasingly complex regulatory environment. Those that incorporate regulatory considerations into investment planning from the outset will be best placed to execute successful transactions and create long-term value.

    *The revised Regulation (Regulation (EU) 2026/1386 of 17 June 2026, replacing Regulation (EU) 2019/452) reached political agreement between the European Parliament and the Council on 11 December 2025, was published in the Official Journal on 26 June 2026, and entered into force on 16 July 2026 (with the relevant obligations applying from 17 January 2028).

    Authors

    Raminta Dereskeviciute

    Partner

    London – 22 Bishopsgate

    Stéphane Dionnet

    Partner

    Brussels

    Jon B. Dubrow

    Partner

    Washington, DC

    Dr. Philipp Grenzebach

    Partner

    Düsseldorf, Frankfurt

    Sabine Naugès

    Partner

    Paris

    More insights